Mural Oncology(MURA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MURA Mural Oncology

Trading 07-01 10:19:06 EDT

3.23

+0.09

+2.71%

High3.29	Low3.14	Vol26.34K
Open3.14	D1 Closing3.14	Amplitude4.78%
Mkt Cap54.58M	Tradable Cap49.23M	Total Shares16.92M
T/O85.09K	T/O Rate0.17%	Tradable Shares15.26M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MURA","market":"US","secType":"STK","nameCN":"Mural Oncology","latestPrice":3.225,"timestamp":1719843481061,"preClose":3.14,"halted":0,"volume":26341,"delay":0,"floatShares":15264669,"shares":16923878,"eps":-11.480032,"marketStatus":"Trading","change":0.085,"latestTime":"07-01 10:19:06 EDT","open":3.14,"high":3.29,"low":3.14,"amount":85094.5873295,"amplitude":0.047771,"askPrice":3.25,"askSize":135,"bidPrice":3.2,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-11.480032,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1719864000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":3.14,"preHourTrading":{"tag":"盘前","latestPrice":3.27,"preClose":3.14,"latestTime":"09:19 EDT","volume":11,"amount":35.9900002,"timestamp":1719839995493},"postHourTrading":{"tag":"盘后","latestPrice":3.14,"preClose":3.14,"latestTime":"16:38 EDT","volume":545437,"amount":1712771.080918,"timestamp":1719607080841},"volumeRatio":0.308064,"impliedVol":2.8247,"impliedVolPercentile":0.75},"requestUrl":"/m/hq/s/MURA","defaultTab":"news","newsList":[{"id":"2447663331","title":"Mural Oncology Initiated at Buy by Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2447663331","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2447663331?lang=en_us&edition=fundamental","pubTime":"2024-06-29 00:57","pubTimestamp":1719593820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 28, 2024 12:57 ET (16:57 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MURA","BK4139"],"gpt_icon":0},{"id":"2441257867","title":"Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2441257867","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441257867?lang=en_us&edition=fundamental","pubTime":"2024-06-05 04:00","pubTimestamp":1717531200,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass. and DUBLIN, June  04, 2024  (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/06/04/2893409/0/en/Mural-Oncology-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4588","BK4112","BK4139","LU2210149790.SGD",".IXIC","NDAQ","BK4585","MURA","LU2095319765.USD"],"gpt_icon":0},{"id":"2437719934","title":"Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2437719934","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2437719934?lang=en_us&edition=fundamental","pubTime":"2024-05-24 05:00","pubTimestamp":1716498000,"startTime":"0","endTime":"0","summary":"ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural’s late-stage lead candidate. Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3 and was generally well-tolerated at all doses tested. Less frequent dosing regimen, a shift from five daily infusions to two infusions per three-week cycle, is being evaluated as both a single agent and in combination with pembrolizumab in patients with cutaneous melanoma in ARTISTRY-6. Preliminary data readouts from the cohorts are expected in 2025. WALTHAM, Mass. and DUBLIN, May 23, 2024  -- Mural Oncology plc , a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today shared data from ARTISTRY-3, a clinical trial designed to evaluate the effects of less frequent intravenous dosing  of nemvaleukin alfa , in advance of the American Society of Clinical Oncolog","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mtrZ7S0S1V9C_hT3L2QLmQ--~B/aD04ODt3PTg4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/23237569ce0500cf957b557e72cbd3bd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mtrZ7S0S1V9C_hT3L2QLmQ--~B/aD04ODt3PTg4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/23237569ce0500cf957b557e72cbd3bd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mural-oncology-presents-clinical-data-210000674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4023","BK4117","MURA","LU1169590202.USD","BK4139","BK4107","LU1169589451.USD","AFG","PD"],"gpt_icon":0},{"id":"2435351999","title":"Mural Oncology GAAP EPS of -$1.84; reaffirms financial guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2435351999","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435351999?lang=en_us&edition=fundamental","pubTime":"2024-05-14 21:41","pubTimestamp":1715694110,"startTime":"0","endTime":"0","summary":"Mural Oncology plc press release : Q1 GAAP EPS of -$1.84. As of March 31, 2024, cash, cash equivalents, and marketable securities were $231.7 million.  Financial Guidance  The company reaffirms guidance that its cash, cash equivalents, and marketable securities are expected to fund its operations into the fourth quarter of 2025.  As noted in the 2023 year-end financial results press release, Mural anticipates reporting lower year-over-year operating expenses in 2024. Also, management forecasts higher operating expenses in 2024 versus 2025 due to the timing of clinical trial expenses.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4105833-mural-oncology-gaap-eps-of-184-reaffirms-financial-guidance","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["MURA"],"gpt_icon":0},{"id":"2435759945","title":"Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2435759945","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435759945?lang=en_us&edition=fundamental","pubTime":"2024-05-14 19:00","pubTimestamp":1715684400,"startTime":"0","endTime":"0","summary":"Mural’s lead product candidate, nemvaleukin alfa, is in two potentially registrational trials in platinum resistant ovarian cancer and mucosal melanoma, both of which are on track with readouts expected in 1H 2025. A new, less frequent IV dose of nemvaleukin is also being evaluated both as a single agent and in combination with pembrolizumab in patients with cutaneous melanoma with preliminary data readouts anticipated in 2025. In April 2024, Mural presented preclinical data on its investigational engineered cytokine therapies targeting IL-18 and IL-12 and continues to expect candidate nominations for each program by the end of 2024. The company reiterates cash runway projection into 4Q 2025, with sufficient capital to fund key clinical readouts. WALTHAM, Mass. and DUBLIN, Ireland, May 14, 2024  -- Mural Oncology plc , a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a vari","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mtrZ7S0S1V9C_hT3L2QLmQ--~B/aD04ODt3PTg4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/23237569ce0500cf957b557e72cbd3bd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mtrZ7S0S1V9C_hT3L2QLmQ--~B/aD04ODt3PTg4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/23237569ce0500cf957b557e72cbd3bd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mural-oncology-announces-first-quarter-110000298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","MURA"],"gpt_icon":0},{"id":"2430985504","title":"Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2430985504","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2430985504?lang=en_us&edition=fundamental","pubTime":"2024-04-24 20:00","pubTimestamp":1713960000,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass. and DUBLIN, Ireland, April  24, 2024  (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytoki","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/24/2869034/0/en/Mural-Oncology-Announces-Upcoming-Presentation-at-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4117","BK4107","AFG","MURA"],"gpt_icon":0},{"id":"2426212395","title":"Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2426212395","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2426212395?lang=en_us&edition=fundamental","pubTime":"2024-04-09 20:00","pubTimestamp":1712664000,"startTime":"0","endTime":"0","summary":"For the first time, the company shares data for its preclinical IL-18 and IL-12 programs—candidate nominations for each are expected later this year Combination of IL-18 binding protein resistance wit","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/09/2860335/0/en/Mural-Oncology-Presents-Preclinical-Data-for-IL-18-and-IL-12-Programs-at-the-2024-American-Association-for-Cancer-Research-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFG","BK4117","BK4107","BK4139","MURA"],"gpt_icon":0},{"id":"2424936329","title":"Mural Oncology’s Buy Rating: Financial Stability and Promising Drug Candidate Propel Growth Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2424936329","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2424936329?lang=en_us&edition=fundamental","pubTime":"2024-04-04 17:06","pubTimestamp":1712221560,"startTime":"0","endTime":"0","summary":"Mural Oncology Plc (MURA) has received a new Buy rating, initiated by Morgan Stanley analyst, Judah Frommer. Judah Frommer has given his Buy rating...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mural-oncologys-buy-rating-financial-stability-and-promising-drug-candidate-propel-growth-prospects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mural-oncologys-buy-rating-financial-stability-and-promising-drug-candidate-propel-growth-prospects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0971096721.USD","LU0106831901.USD","BK4504","BK4139","MURA","LU0320765646.SGD","IE00BZ1G4Q59.USD","LU1162221912.USD","LU1989772923.USD","LU1668664300.SGD","LU1074936037.SGD","BK4581","BK4534","LU0098860793.USD","BK4585","BK4127","LU1989772840.SGD","LU1363072403.SGD","BK4588","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2422611179","title":"Mural Oncology plc GAAP EPS of -$3.57","url":"https://stock-news.laohu8.com/highlight/detail?id=2422611179","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2422611179?lang=en_us&edition=fundamental","pubTime":"2024-03-26 22:21","pubTimestamp":1711462913,"startTime":"0","endTime":"0","summary":"Mural Oncology plc press release  (NASDAQ:MURA): Q4  GAAP EPS of -$3.57.\n cash and cash equivalents were $270.9 million.\n\n\n\n\nMore on Mural Oncology plc  Recent Spin Mural Oncology At An Attractive Discount To Cash And Portfolio Value Financial information for Mural Oncology plc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4083722-mural-oncology-plc-gaap-eps-of-3_57","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["MURA"],"gpt_icon":0},{"id":"2422932586","title":"Mural Oncology Q4 EPS $(3.57) Down From $(2.91) YoY, Cash Balance of $270.9M","url":"https://stock-news.laohu8.com/highlight/detail?id=2422932586","media":"Benzinga","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2422932586?lang=en_us&edition=fundamental","pubTime":"2024-03-26 19:18","pubTimestamp":1711451937,"startTime":"0","endTime":"0","summary":"Mural Oncology (NASDAQ:MURA) reported quarterly losses of $(3.57) per share. This is a 22.68 percent decrease over losses of $(2.91) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/03/37930245/mural-oncology-q4-eps-3-57-down-from-2-91-yoy-cash-balance-of-270-9m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MURA"],"gpt_icon":0},{"id":"2422693854","title":"Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2422693854","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2422693854?lang=en_us&edition=fundamental","pubTime":"2024-03-26 11:00","pubTimestamp":1711422000,"startTime":"0","endTime":"0","summary":"Lead product candidate, nemvaleukin, is being developed to treat a wide range of solid tumors and is currently in two potentially registrational clinical trials with readouts for both expected in 1H 2","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/03/26/2852212/0/en/Mural-Oncology-Announces-Fourth-Quarter-and-Year-End-2023-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MURA"],"gpt_icon":0},{"id":"2417420269","title":"Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2417420269","media":"StreetInsider","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2417420269?lang=en_us&edition=fundamental","pubTime":"2024-03-06 05:35","pubTimestamp":1709674500,"startTime":"0","endTime":"0","summary":"Source: Mural Oncology, Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22887393","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["BK4139","MURA"],"gpt_icon":0},{"id":"2417177927","title":"Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2417177927","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2417177927?lang=en_us&edition=fundamental","pubTime":"2024-03-04 21:15","pubTimestamp":1709558100,"startTime":"0","endTime":"0","summary":"DUBLIN, Ireland, March  04, 2024  (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/03/04/2839987/0/en/Mural-Oncology-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NDAQ","LU2095319765.USD","LU2210149790.SGD","MURA","LU2210150020.SGD",".IXIC","BK4112","BK4588","BK4585"],"gpt_icon":0},{"id":"2409468843","title":"Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2409468843","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2409468843?lang=en_us&edition=fundamental","pubTime":"2024-02-05 21:30","pubTimestamp":1707139800,"startTime":"0","endTime":"0","summary":"DUBLIN, Ireland, Feb.  05, 2024  (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/02/05/2823874/0/en/Mural-Oncology-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","MURA",".IXIC","BK4112","LU2210149790.SGD","BK4139","LU2210150020.SGD","NDAQ","BK4585","BK4588"],"gpt_icon":0},{"id":"2406710303","title":"Alkermes: Slimmed-Down Pharma Not A Compelling Growth Story Yet","url":"https://stock-news.laohu8.com/highlight/detail?id=2406710303","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2406710303?lang=en_us&edition=fundamental","pubTime":"2024-01-27 03:15","pubTimestamp":1706296533,"startTime":"0","endTime":"0","summary":"Alkermes plc, a neuroscience company, has undergone restructuring and simplification, including spinning out its oncology business and selling its manufacturing facility.Despite a turbulent year, Alke","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1457349338/image_1457349338.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1457349338/image_1457349338.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4665348-alkermes-slimmed-down-pharma-not-a-compelling-growth-story-yet","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LU1814569148.SGD","LU0672654240.SGD","SG9999013999.USD","AVDL","LU0417517546.SGD","LU0234572021.USD","ALKS","BK4139","LU0320765059.SGD","SG9999002232.USD","BK4588","LU2347655156.SGD","BK4592","BK4581","LU2237438978.USD","NVO","IE00B2B36J28.USD","LU1988902786.USD","LU1732800096.USD","IE0002270589.USD","LU1244550494.USD","LU1023059063.AUD","LU2468319806.SGD","LU0640476718.USD","SG9999001440.SGD","LU1032466523.USD","LU1430594728.SGD","LU1267930730.SGD","IE00B19Z3581.USD","LLY","LU0289739699.SGD","LU0912757837.SGD","LU1064131342.USD","LU1585245621.USD","LU2602419157.SGD","LU1244550577.SGD","JNJ","LU0198837287.USD","LU1057294990.SGD","ITCI","SG9999002224.SGD","BK4585","LU0456855351.SGD","MURA","TEVA","LU0795875086.SGD","LU2133065610.SGD","LU0792757196.USD","BK4504","LU1267930813.SGD"],"gpt_icon":0},{"id":"2403191022","title":"The 3 Most Undervalued Biotech Stocks to Buy in January","url":"https://stock-news.laohu8.com/highlight/detail?id=2403191022","media":"InvestorPlace","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2403191022?lang=en_us&edition=fundamental","pubTime":"2024-01-16 05:51","pubTimestamp":1705355467,"startTime":"0","endTime":"0","summary":"These are a few biotechnology stocks that the market has undervalued at this time.Alkermes is an Irish-based biotech firm that produces pharmaceuticals.MacroGenics: They are a biopharmaceutical company that provides treatments for cancer.Heron Therapeutics: it is a company that develops a number of different types of drug technology.Alkermes reportedearnings for the third quarterof 2023 on Oct. 25, which stated that their total revenue increased by 51% compared to the previous year. They also reported earnings per share of twenty-eight cents per share for the third quarter. Their jump in overall revenue is partly due to the increased profitability of Lybalvi, their flagship psychiatric drug, which saw a year-over-year increase in sales of 87%.MacroGenics  is a pharmaceutical company with a broad range of treatments for different types of cancer. Their flagship medication at this time is Margenza, which is used to treat breast cancer. They also have several other therapies in phase 1 an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/2024/01/the-3-most-undervalued-biotech-stocks-to-buy-in-january/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investorplace_stock_picks","symbols":["MNQmain","QLD","PSQ","QQQ","MURA","TQQQ","HRTX","ALKS","SQQQ","QID","BK4139","MGNX",".IXIC","NQmain"],"gpt_icon":0},{"id":"2402170487","title":"Westfield Capital Management Company Reports 11.9% Passive Stake In Mural Oncology As Of Dec 29, 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2402170487","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2402170487?lang=en_us&edition=fundamental","pubTime":"2024-01-10 19:21","pubTimestamp":1704885669,"startTime":"0","endTime":"0","summary":"Mural Oncology PLC :Westfield Capital Management Company, Lp Reports 11.9% Passive Stake In Mural Oncology Plc As Of Dec 29, 2023 - Sec Filing.Further Company Coverage: Mura.O. ((Reuters.Briefs@Thomsonreuters.Com;)).","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.trkd.thomsonreuters.com","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MURA","BK4139"],"gpt_icon":0},{"id":"2401959805","title":"BRIEF-Mural Oncology Announces Enhancements To Late-Stage Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2401959805","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2401959805?lang=en_us&edition=fundamental","pubTime":"2024-01-08 21:50","pubTimestamp":1704721859,"startTime":"0","endTime":"0","summary":"Jan 8  - Mural Oncology PLC   :   * MURAL ONCOLOGY ANNOUNCES ENHANCEMENTS TO LATE-STAGE CLINICAL TRIALS   * STRATEGIC CHANGES TO ARTISTRY-6 AND ARTISTRY-7 CLINICAL TRIALS DESIGNED TO GENERATE MORE MEANINGFUL CLINICAL DATA FOR  LATE-STAGE   * INTENDS TO NOMINATE DEVELOPMENT CANDIDATES FOR  ENGINEERED THERAPIES TARGETING INTERLEUKIN-18 AND INTERLEUKIN-12 PROGRAMS IN 2024   * REITERATES CURRENT CASH RUNWAY PROJECTION INTO 4Q 2025Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MURA","SSI"],"gpt_icon":0},{"id":"2401093789","title":"Mural Oncology Announces Enhancements to Late-Stage Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2401093789","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2401093789?lang=en_us&edition=fundamental","pubTime":"2024-01-08 20:00","pubTimestamp":1704715200,"startTime":"0","endTime":"0","summary":"Strategic changes to ARTISTRY-6 and ARTISTRY-7, both potentially registrational trials of nemvaleukin, are intended to result in more clinically meaningful data. Mural intends to nominate development candidates for its engineered therapies targeting interleukin-18 and interleukin-12 programs in 2024. The Company reiterates current cash runway projection into 4Q 2025. DUBLIN, Ireland, Jan. 08, 2024  -- Mural Oncology plc , a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, announced strategic changes to its ARTISTRY-6 and ARTISTRY-7 clinical trials designed to generate more meaningful clinical data for these late-stage, potentially registrational trials of nemvaleukin.Cohort 2 of ARTISTRY-6 is a potentially registrational, phase 2 trial evaluating nemvaleukin as a monotherapy in mucosal melanoma patients. Mural plans to increase the size of this cohort by","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mtrZ7S0S1V9C_hT3L2QLmQ--~B/aD04ODt3PTg4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/23237569ce0500cf957b557e72cbd3bd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mtrZ7S0S1V9C_hT3L2QLmQ--~B/aD04ODt3PTg4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/23237569ce0500cf957b557e72cbd3bd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mural-oncology-announces-enhancements-stage-120000619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MURA","BK4211","BK4195","SSI","BK4139","PFS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.muraloncology.com","stockEarnings":[{"period":"1week","weight":-0.0309},{"period":"1month","weight":-0.0627},{"period":"3month","weight":-0.3579},{"period":"6month","weight":-0.4696},{"period":"1year","weight":-0.9451},{"period":"ytd","weight":-0.4696}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":0.0344},{"period":"3month","weight":0.0404},{"period":"6month","weight":0.145},{"period":"1year","weight":0.2422},{"period":"ytd","weight":0.145}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.","exchange":"NASDAQ","name":"Mural Oncology","nameEN":"Mural Oncology"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mural Oncology(MURA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mural Oncology(MURA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mural Oncology,MURA,Mural Oncology股票,Mural Oncology股票老虎,Mural Oncology股票老虎国际,Mural Oncology行情,Mural Oncology股票行情,Mural Oncology股价,Mural Oncology股市,Mural Oncology股票价格,Mural Oncology股票交易,Mural Oncology股票购买,Mural Oncology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mural Oncology(MURA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mural Oncology(MURA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}